(PFE) Pfizer - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 147.901m USD | Total Return: 20.7% in 12m
Avg Turnover: 929M
EPS Trend: 23.8%
Qual. Beats: 0
Rev. Trend: -24.4%
Qual. Beats: 0
Warnings
Choppy
Tailwinds
No distinct edge detected
Pfizer Inc. is a global biopharmaceutical company engaged in the research, development, and distribution of medicines and vaccines. The firm operates through three primary segments: Biopharma, PC1, and Pfizer Ignite. Its product portfolio spans internal medicine, oncology, immunology, and rare diseases, featuring established brands such as Eliquis, Prevnar, and Ibrance. Pfizer utilizes a diversified business model that combines internal R&D with strategic collaborations, such as its partnership with BioNTech for mRNA technology.
The pharmaceutical sector is characterized by high capital expenditures and long regulatory lead times, often requiring decades to bring a single molecule to market. Pfizer maintains a competitive position through its extensive pipeline of antibody-drug conjugates (ADCs) and small molecule therapies. The company has recently expanded its technological capabilities by integrating AI foundation models into its drug discovery process. For a deeper look at these fundamentals, you may find ValueRays detailed analysis useful.
Headquartered in New York and founded in 1849, Pfizer remains one of the largest patent-holding entities in the healthcare industry. Its revenue streams are globally diversified, supported by a mix of specialized oncology treatments and high-volume sterile injectables. The company continues to manage a broad range of biosimilars and anti-infective medicines across international markets.
- Seagen acquisition integration determines long-term oncology revenue and margin expansion
- COVID-19 product demand volatility impacts annual earnings and cash flow stability
- Vyndaqel and Eliquis sales growth offsets upcoming patent expirations on legacy brands
- New product launch execution across immunology and vaccines dictates mid-term valuation
- Cost realignment initiatives and R&D efficiency targets influence operational profit margins
| Net Income: 7.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.83 > 1.0 |
| NWC/Revenue: 13.38% < 20% (prev 15.06%; Δ -1.68% < -1%) |
| CFO/TA 0.06 > 3% & CFO 12.0b > Net Income 7.49b |
| Net Debt (51.4b) to EBITDA (16.9b): 3.03 < 3 |
| Current Ratio: 1.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.73b) vs 12m ago 0.37% < -2% |
| Gross Margin: 69.35% > 18% (prev 0.67%; Δ 6.87k% > 0.5%) |
| Asset Turnover: 30.47% > 50% (prev 30.03%; Δ 0.44% > 0%) |
| Interest Coverage Ratio: 4.02 > 6 (EBITDA TTM 16.9b / Interest Expense TTM 2.69b) |
| A: 0.04 (Total Current Assets 42.8b - Total Current Liabilities 34.3b) / Total Assets 208b |
| B: 0.56 (Retained Earnings 117b / Total Assets 208b) |
| C: 0.05 (EBIT TTM 10.8b / Avg Total Assets 208b) |
| D: 0.94 (Book Value of Equity 111b / Total Liabilities 117b) |
| Altman-Z'' = 3.45 = A |
| DSRI: 0.84 (Receivables 12.6b/14.7b, Revenue 63.3b/62.5b) |
| GMI: 0.97 (GM 69.35% / 66.93%) |
| AQI: 1.01 (AQ_t 0.70 / AQ_t-1 0.69) |
| SGI: 1.01 (Revenue 63.3b / 62.5b) |
| TATA: -0.02 (NI 7.49b - CFO 12.0b) / TA 208b) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of May 29, 2026, the stock is trading at USD 26.14 with a total of 19,299,240 shares traded.
Over the past week, the price has changed by +1.36%,
over one month by +0.35%,
over three months by -3.90% and
over the past year by +20.65%.
Pfizer has received a consensus analysts rating of 3.56. Therefore, it is recommended to hold PFE.
- StrongBuy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 29.2 | 11.7% |
P/E Trailing = 19.8092
P/E Forward = 8.8417
P/S = 2.3359
P/B = 1.6415
P/EG = 13.7734
Revenue TTM = 63.3b USD
EBIT TTM = 10.8b USD
EBITDA TTM = 16.9b USD
Long Term Debt = 59.8b USD (from longTermDebt, last quarter)
Short Term Debt = 3.89b USD (from shortTermDebt, last quarter)
Debt = 64.5b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 51.4b USD (calculated: Debt 64.5b - CCE 13.1b)
Enterprise Value = 199b USD (148b + Debt 64.5b - CCE 13.1b)
Interest Coverage Ratio = 4.02 (Ebit TTM 10.8b / Interest Expense TTM 2.69b)
EV/FCF = 21.01x (Enterprise Value 199b / FCF TTM 9.48b)
FCF Yield = 4.76% (FCF TTM 9.48b / Enterprise Value 199b)
FCF Margin = 14.98% (FCF TTM 9.48b / Revenue TTM 63.3b)
Net Margin = 11.83% (Net Income TTM 7.49b / Revenue TTM 63.3b)
Gross Margin = 69.35% ((Revenue TTM 63.3b - Cost of Revenue TTM 19.4b) / Revenue TTM)
Gross Margin QoQ = 67.26% (prev 69.97%)
Tobins Q-Ratio = 0.96 (Enterprise Value 199b / Total Assets 208b)
Interest Expense / Debt = 4.17% (Interest Expense 2.69b / Debt 64.5b)
Taxrate = 14.54% (461.0m / 3.17b)
NOPAT = 9.22b (EBIT 10.8b * (1 - 14.54%))
Current Ratio = 1.25 (Total Current Assets 42.8b / Total Current Liabilities 34.3b)
Debt / Equity = 0.72 (Debt 64.5b / totalStockholderEquity, last quarter 90.1b)
Debt / EBITDA = 3.03 (Net Debt 51.4b / EBITDA 16.9b)
Debt / FCF = 5.42 (Net Debt 51.4b / FCF TTM 9.48b)
Total Stockholder Equity = 89.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 7.49b / Total Assets 208b)
RoE = 8.37% (Net Income TTM 7.49b / Total Stockholder Equity 89.5b)
RoCE = 7.22% (EBIT 10.8b / Capital Employed (Equity 89.5b + L.T.Debt 59.8b))
RoIC = 5.20% (NOPAT 9.22b / Invested Capital 177b)
WACC = 6.28% (E(148b)/V(212b) * Re(7.47%) + D(64.5b)/V(212b) * Rd(4.17%) * (1-Tc(0.15)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 0.66%
[DCF] Terminal Value 73.10% ; FCFF base≈10.2b ; Y1≈8.93b ; Y5≈7.21b
[DCF] Fair Price = 11.30 (EV 116b - Net Debt 51.4b = Equity 64.4b / Shares 5.70b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 23.79 | EPS CAGR: 10.46% | SUE: 0.27 | # QB: 0
Revenue Correlation: -24.44 | Revenue CAGR: -2.41% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.68 | Chg30d=+0.34% | Revisions=-5% | Analysts=18
EPS next Quarter (2026-09-30): EPS=0.85 | Chg30d=-1.78% | Revisions=+10% | Analysts=18
EPS current Year (2026-12-31): EPS=2.96 | Chg30d=+0.02% | Revisions=+8% | GrowthEPS=-8.0% | GrowthRev=-1.4%
EPS next Year (2027-12-31): EPS=2.84 | Chg30d=+0.87% | Revisions=+17% | GrowthEPS=-4.2% | GrowthRev=-3.8%
[Analyst] Revisions Ratio: +17%